In the early 80s the collection of Pancratium found a very potent anticancer constituent, pancratistatin. Subsequently, the U.S. National Cancer Institute initiated preclinical development of pancratistatin due to its high level of in vitro and in vivo cancer cell growth inhibitory. Unfortunately, the preclinical development slowed by severe supply...